journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://www.readbyqxmd.com/read/28412781/molecular-testing-to-optimize-and-personalize-decision-making-in-the-management-of-colorectal-cancer
#1
REVIEW
Marwan Al-Hajeili, Anthony F Shields, Jimmy J Hwang, Raymond C Wadlow, John L Marshall
Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient. Proper utilization of these biomarkers can enable physicians to tailor therapeutic strategies to maximize the likelihood of response and minimize treatment toxicity. In the management of colorectal cancer, tremendous progress has been made in the development of strategies for immune checkpoint inhibition; in refinement of agents and approaches used in targeted therapy; and in techniques for molecular subtyping of tumor samples that have identified patient subgroups with clinically relevant cellular differences potentially affecting clinical management and treatment outcome...
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412780/how-can-we-effectively-address-the-medical-and-psychological-concerns-of-survivors-of-pelvic-malignancies
#2
REVIEW
Ramiro Jose Madden-Fuentes, Bridget F Koontz, Michael R Harrison, Daniel J George, Brittany Davidson, Brian F Gilmore, Judd W Moul, Christopher Mantyh, Andrew C Peterson
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. These treatment sequelae are significantly bothersome to patients and challenging to address. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management. Addressing these issues often necessitates a coordinated multidisciplinary approach; however, the effort required often translates into improvement in patient quality of life...
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412779/synchronous-bilateral-breast-cancer-with-discordant-histology
#3
Mehmet Sitki Copur, Ryan Ramaekers, Dron Gauchan, David Crockett, Douglas Clark
No abstract text is available yet for this article.
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412778/parp-inhibitors-the-cornerstone-of-dna-repair-targeted-therapies
#4
REVIEW
Jaydira Del Rivero, Elise C Kohn
The activity and therapeutic licensing of poly(ADP-ribose) polymerase (PARP) inhibitors is the culmination of 50 years of research. However, the biology, mechanisms of action, adequate treatment combinations, and targeted populations for these agents need to be explored further. PARP activity is essential for the repair of single-strand DNA breaks via the base excision repair pathway. This pathway is the default repair pathway in cells with deficient high-fidelity double-strand break homologous recombination (HR) repair, such as occurs with loss of BRCA1 or BRCA2 function...
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412777/how-to-address-sexual-problems-in-female-cancer-patients
#5
Eleonora P Preti, Fabio Landoni, Nicoletta Colombo, Don S Dizon
Sexual health is an important aspect of human life, and cancer does not (and should not) change that. Data suggest that issues related to sexual function are quite common among women treated for cancer. However, clinicians often spend little to no time on the topic. This article provides a concise summary on the importance of sexual health among women treated for cancer, as well as an approach that general cancer clinicians can adopt in order to normalize sexual health issues for their patients. Finally, we provide an overview of sexual health therapeutics available in the United States and in Europe...
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412776/defining-the-value-research-agenda-in-radiation-oncology
#6
David J Sher
No abstract text is available yet for this article.
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412775/defining-value-in-radiation-oncology-approaches-to-weighing-benefits-vs-costs
#7
REVIEW
Andre A Konski
The passage of the Affordable Care Act in 2010 initiated discussion regarding transitioning from a fee-for-service arrangement of care reimbursement to value-based care. Cost-effectiveness analysis (CEA) has been used in the past to quantify value as it relates to the provision of healthcare. New treatments or techniques being compared with other new or existing therapies or approaches to care were determined to be cost-effective if the incremental cost-effectiveness ratio was less than $50,000/life-year or quality-adjusted life-year...
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28412774/treating-the-patient-not-the-disease-fred-schiffman-on-humanism-in-medicine
#8
Fred Schiffman
No abstract text is available yet for this article.
April 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299760/uterine-sarcomas-the-latest-approaches-for-these-rare-but-potentially-deadly-tumors
#9
REVIEW
Jing-Yi Chern, Leslie R Boyd, Stephanie V Blank
Uterine sarcomas are rare malignant uterine neoplasms that are responsible for a large majority of uterine cancer-associated deaths. The subtypes include leiomyosarcomas, endometrial stromal tumors, and adenosarcomas. Standard treatment includes complete surgical resection. Adjuvant treatment with chemotherapy, hormonal therapy, or radiation may be considered in patients with high-risk disease. However, because the ability of adjuvant treatment to improve overall survival in patients with uterine sarcomas is unclear, there is no standard recommendation regarding adjuvant therapy...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299759/optimizing-the-benefit-of-cns-radiation-therapy-in-the-pediatric-population-part-2-novel-methods-of-radiation-delivery
#10
REVIEW
Lindsay S Rowe, Andra V Krauze, Holly Ning, Kevin A Camphausen, Aradhana Kaushal
Newer approaches in the field of radiation therapy have raised the bar in the treatment of central nervous system (CNS) malignancies, with recognized advances that have aimed to increase the therapeutic index by improving conformality of the radiation dose to the planned target volume. Beyond these advances, the continued evolution of more effective systems for delivery of radiation to the CNS may offer further benefit not only to adults but also to pediatric patients, a cohort of the population that may be more sensitive to the long-term effects of radiation...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299758/seventy-year-old-man-with-large-bladder-mass-diagnostic-and-clinical-challenges-of-an-uncommon-neoplasm
#11
Tamara P Lhungay, Alexandra Colvin, Jason Warncke, Hilary Somerset, Shandra S Wilson, Francisco G La Rosa
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299757/nanoparticle-delivered-chemotherapy-old-drugs-in-new-packages
#12
REVIEW
Michael S Lee, E Claire Dees, Andrew Z Wang
Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic chemotherapy drugs can enhance pharmacokinetic characteristics and facilitate passive targeting of drugs to tumors via the enhanced permeability and retention effect, thus mitigating toxicity. Nanoparticle vehicles currently in clinical use or undergoing clinical investigation for anticancer therapies include liposomes, polymeric micelles, protein-drug nanoparticles, and dendrimers...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299756/counterpoint-standard-vs-investigational-agents-as-upfront-treatment-for-high-risk-aml
#13
Andrew M Brunner, Wendy Stock
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299755/point-standard-vs-investigational-agents-as-upfront-treatment-for-high-risk-aml
#14
Charles A Schiffer
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299754/optimizing-the-benefit-of-cns-radiation-therapy-in-the-pediatric-population-part-1-understanding-and-managing-acute-and-late-toxicities
#15
REVIEW
Lindsay S Rowe, Andra V Krauze, Holly Ning, Kevin A Camphausen, Aradhana Kaushal
Radiation therapy continues to be a key component in the management of pediatric malignancies. Increasing the likelihood of cure while minimizing late treatment toxicity in these young patients remains the primary goal. Within the realm of central nervous system neoplasms, efforts to further improve the efficacy of radiation therapy continue, while balancing risks of damage to uninvolved tissue. Radiation therapy can result in second malignancies, as well as cerebrovascular, neurotoxic, neurocognitive, endocrine, psychosocial, and quality-of-life effects...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299753/pubic-bone-osteomyelitis-and-pubosymphyseal-urinary-fistula-a-poorly-recognized-complication-in-prostate-cancer-survivors
#16
Ramiro Jose Madden-Fuentes, Andrew C Peterson
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299752/therapeutic-implications-of-molecular-subtyping-for-pancreatic-cancer
#17
REVIEW
Michael J Pishvaian, Jonathan R Brody
The prognosis of metastatic pancreatic adenocarcinoma has recently begun to improve. In the last several years, first-line therapy with gemcitabine plus nab-paclitaxel or a regimen of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has boosted the median overall survival (OS) duration to 8.5 months and 11 months, respectively, in patients with metastatic pancreatic cancer, compared with a historic OS of only 6 months prior to 2011. Moreover, sequencing these two regimens improved median OS to an unprecedented 18 months...
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28299751/maurie-markman-on-the-groundbreaking-tapur-trial
#18
Maurie Markman
No abstract text is available yet for this article.
March 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205194/novel-and-expanded-oncology-drug-approvals-of-2016-part-2-new-options-in-the-management-of-hematologic-malignancies
#19
REVIEW
Todd C Knepper, James Saller, Christine M Walko
The recent past has brought pharmacotherapeutic advances that benefit patients with hematologic malignancies. In 2016, two novel hematology drugs were approved and four previously approved hematology drugs were granted expanded use for the treatment of appropriate patient populations by the US Food and Drug Administration. These new approvals and indications represent significant steps forward in patient management: they include the first-in-class B-cell lymphoma 2 inhibitor, venetoclax, the newest targeted therapy available for the treatment of hematologic malignancies; and nivolumab, the first immune checkpoint inhibitor to be approved for treatment of a hematologic malignancy...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205193/new-therapeutic-strategies-for-triple-negative-breast-cancer
#20
REVIEW
Borbála Székely, Andrea L M Silber, Lajos Pusztai
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options such as immune checkpoint inhibitors and antibody-drug conjugates. Evidence also increasingly supports that platinum drugs and inhibitors of poly (ADP-ribose) polymerase, or PARP, are particularly effective in the treatment of germline BRCA-mutant cancers, including TNBC...
February 15, 2017: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"